Business Development & Licensing: Seeking relevant commercialization partners

Our expertise covers the full drug development value chain from preclinical to registration, including clinical development, translational medicine, CMC, regulatory affairs, and business and commercial activities. Our 400 scientists are dedicated to innovation bringing the best medicines to patients Our privately owned status gives us the freedom and financial capabilities to support the development costs and associated risks. Once we have proven the safety and efficacy of the compound, we seek relevant partners for commercialization and optimization of patient access worldwide.

How do we bring innovative treatments to patients worldwide

Our collaborative business model involves partnering with global pharmaceutical companies for our growing pipeline of oncology and infectious disease products. If you’re looking for innovative oncology treatments or novel antibiotics, think Debiopharm!


We currently have a growing pipeline of projects in development in the areas of oncology, infectious disease, and antibody-drug conjugate (ADC) drug technology.


  • Debio 0123 - WEE1 Kinase inhibitor, Oncology

  • Debio 0228 - CA IX-targeted radioligand, Oncology

  • Debio 4126 - Long-acting octreotide, Acromegaly

  • Debio 1450 - FabI inhibitor, afabicin antibiotics

Sandra von Meier Head of Business Development & Licensing

We have several projects ready for out-licensing and we are looking for partners

Get in touch

Our success stories

  • GnRH agonist analogue Triptorelin

    Triptorelin is a standard-of-care treatment for advanced prostate cancer and an emerging therapy for endometriosis, in-vitro fertilization programs, uterine fibroids, precocious puberty

    More info
  • Platinum-based chemotherapy Oxaliplatin

    Oxaliplatin is a diaminocyclohexane (DACH) platin, for the treatment of colorectal cancer

    More info
  • Xevinapant

    Xevinapant (Debio 1143) is a potent, orally available, inhibitor of IAPs for the treatment of head and neck cancer. It is under an exclusive license agreement with Merck for product development and commercialization

    More info